{"id":10778,"date":"2026-04-06T11:02:44","date_gmt":"2026-04-06T16:02:44","guid":{"rendered":"https:\/\/www.appliedpolicy.com\/staging\/7403\/?p=10778"},"modified":"2026-04-06T11:09:34","modified_gmt":"2026-04-06T16:09:34","slug":"president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year","status":"publish","type":"post","link":"https:\/\/www.appliedpolicy.com\/staging\/7403\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\/","title":{"rendered":"President Trump’s EO on Lowering Drug Prices by Putting Americans First at One Year"},"content":{"rendered":"

A year after President Trump issued Executive Order (EO) 14273, Lowering Drug Prices by Once Again Putting Americans First<\/em><\/a>, federal agencies continue to take steps to advance its objectives.<\/p>\n

Although the EO\u2019s deadlines and goals are not immediately enforceable, they provide insight into the Trump Administration\u2019s drug pricing priorities and the timing of implementation. The Trump Administration has taken steps to complete many of the directives below, though several remain in the rulemaking phase and have yet to be fully implemented.<\/p>\n

Some directives ask agency officials to provide recommendations to the President but do not specifically require them to be publicly released. For these actions, work may be ongoing without public visibility.<\/p>\n

Building on our August 2025 analysis<\/a>, the chart below outlines the EO directives, implementation timing, and agency actions to date in the chart below. Applied Policy continues to track implementation efforts and is ready to help stakeholders navigate the implications of each directive.<\/p>\n

 <\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
EO Directive<\/th>\nEO-Directed Timing<\/th>\nRelease Date<\/th>\nAgency Actions<\/th>\n<\/tr>\n<\/thead>\n
Sec. 3. Improving upon the Inflation Reduction Act<\/strong>
\nRelease Medicare Drug Price Negotiation Program Guidance for IPAY 2028 and MFP Effectuation for IPAY 2026\u20132028<\/td>\n		June 14, 2025<\/td>\n\n
May 12, 2025<\/div>\n
September 30, 2025<\/div>\n<\/td>\n
\n
Sec. 8. Reevaluating the Role of Middlemen<\/strong>
\nRecommendations promoting lower drug prices in the pharmaceutical supply chain<\/td>\n		July 14, 2025<\/td>\nNo recommendations have been publicly released<\/td>\nNo recommendations have been publicly released, but the Consolidated Appropriations Act, 2026<\/a>, includes significant changes to pharmacy benefit manager (PBM) oversight and transparency.<\/td>\n<\/tr>\n
Sec. 7. Access to Affordable Life-Saving Medications<\/strong>
\nAccess to insulin and injectable epinephrine at or below 340B acquisition cost<\/td>\n		July 14, 2025<\/td>\nJune 24, 2025<\/td>\nThe Health Resources and Services Administration (HRSA) announced <\/a>actions to lower out-of-pocket costs for insulin and injectable epinephrine for low-income patients receiving these products from HRSA-funded health centers by issuing updated award terms that align with the EO requirements.<\/td>\n<\/tr>\n
Sec. 10. Increasing Prescription Drug Importation to Lower Prices<\/strong>
\nSteps to increase importation<\/td>\n		July 14, 2025<\/td>\nMay 21, 2025<\/td>\n\n
FDA issued a press release outlining steps to enhance state and tribal importation programs under section 804 of the Federal Food, Drug, and Cosmetic Act.<\/div>\n
These include: (1) a pre-review option for draft proposals and informal FDA feedback prior to formally submitting their section 804 importation program (SIP) proposal; (2) development of a user-friendly proposal tool; and (3) additional support for states in conducting required cost savings analyses.<\/div>\n<\/td>\n<\/tr>\n
Sec. 3. Improving upon the Inflation Reduction Act<\/strong>
\nRecommendations to stabilize and reduce Medicare Part D premiums<\/td>\n		October 12, 2025<\/td>\nJuly 28, 2025<\/td>\nOn July 28, 2025, CMS released the 2026 Medicare Part D Bid Information and Part D Premium Stabilization Demonstration Parameters<\/a>. The base beneficiary premium for 2026 will be $38.99, a 6% increase from last year\u2019s premium. Under the Inflation Reduction Act (IRA), the annual increase in the base beneficiary premium is not to exceed 6% per year. CMS will also continue with the voluntary Part D Premium Stabilization Demonstration, which began last year to stabilize year-over-year changes in premiums for standalone prescription drug plans (PDPs) as the IRA\u2019s Part D benefit redesign is ongoing. CMS is updating parameters for the demonstration this year by reducing the uniform base beneficiary premium reduction from $15 to $10, increasing the limit on a plan\u2019s total Part D premium increase from $35 to $50, and ending narrowed risk corridor thresholds.<\/td>\n<\/tr>\n
Sec. 9. Accelerating Competition for High-Cost Prescription Drugs<\/strong>
\nRecommendations on increasing access to generics, biosimilars, combination products, second-in-class brand name medications, and OTC medications<\/td>\n		October 12, 2025<\/td>\nNo recommendations have been publicly released<\/td>\nNo recommendations have been released, but FDA has taken actions to expedite development for generics and biosimilars, including by streamlining biosimilar study requirements<\/a> and prioritizing review of ANDAs that are domestically manufactured and tested<\/a>.<\/td>\n<\/tr>\n
Sec. 5. Appropriately Accounting for Acquisition Costs of Drugs in Medicare<\/strong>
\nPlan to survey hospital acquisition cost for outpatient drugs<\/td>\n		October 12, 2025<\/td>\n\n\n
In the Calendar Year (CY) 2026 Outpatient Prospective Payment System (OPPS) Final Rule, CMS finalized its intent to conduct a survey to inform CY 2027 payment policy.<\/div>\n
The survey follows the June 2022 Supreme Court decision in American Hospital Association v. Becerra<\/em>, which held that HHS may not vary payment rates for drugs and biologicals among hospital groups without first conducting an acquisition cost survey.<\/div>\n
Sec. 12. Improving Transparency into PBM Fee Disclosure<\/strong>
\nPropose ERISA-related fiduciary transparency regulations<\/td>\n		October 12, 2025<\/td>\nJanuary 29, 2026<\/td>\n\n
On January 29, 2026, the Department of Labor\u2019s Employee Benefits Security Administration proposed the Improving Transparency into Pharmacy Benefit Manager Fee Disclosure Rule<\/a>. Comments are due April 15, 2026.<\/div>\n
This rule would require PBMs to disclose compensation to self-insured group health plans. Specifically, PBMs would be required to disclose:<\/div>\n
    \n
  • Payments from drug manufacturers, including rebates<\/li>\n
  • Compensation received when the price a plan pays for a prescription drug is greater than the amount reimbursed to the pharmacy<\/li>\n
  • Payments recouped from pharmacies connected with prescription drugs dispensed to the plan<\/li>\n<\/ul>\n
    DOL also proposes to allow plan fiduciaries to audit PBM disclosures for accuracy at least once per year and outlines what plan fiduciaries may do if their PBMs do not meet the required disclosures.<\/div>\n<\/td>\n<\/tr>\n
Sec. 11. Reducing Costly Care for Seniors<\/strong>
\nSite-neutral payment for drug administration<\/td>\n		October 12, 2025<\/td>\nNovember 21, 2025<\/td>\nIn the CY 2026 OPPS Final Rule, CMS finalized policies to align payment rates for drug administration in off-campus provider-based departments with those in the physician office setting, a step toward site neutrality. CMS also sought feedback on potentially expanding site neutrality in the proposed rule. See Applied Policy\u2019s summary<\/a> of the OPPS Final Rule for more details.<\/td>\n<\/tr>\n
Sec. 6. Promoting Innovation, Value, and Enhanced Oversight in Medicaid Drug Payment<\/strong>
\nRecommendations on Medicaid drug pricing reform<\/td>\n		October 12, 2025<\/td>\nNo recommendations have been publicly released<\/td>\nCMS has released the voluntary GENEROUS Model<\/a>, and MFN agreements include MFN pricing for drugs in Medicaid. However, no report on recommendations on Medicaid drug pricing reform has been released.<\/td>\n<\/tr>\n
Sec. 13. Combating Anti-Competitive Behavior by Prescription Drug Manufacturers<\/strong>
\nListening sessions and report<\/td>\n		October 12, 2025<\/td>\nListening sessions were held June 30, July 24, and August 4; report has not been released.<\/td>\n\n
The FTC held three listening sessions addressing anticompetitive conduct, formulary and benefit design practices, and policy approaches to reduce drug prices.<\/div>\n
These sessions will inform a forthcoming report on manufacturer behavior. The report has not yet been released.<\/div>\n
The listening sessions will inform the report on combating anti-competitive manufacturer behavior.<\/div>\n
Read Applied Policy\u2019s summaries of the three listening sessions: here<\/a>, here<\/a>, and here<\/a>.<\/div>\n<\/td>\n<\/tr>\n
Sec. 4. Reducing the Prices of High-Cost Drugs for Seniors<\/strong>
\nRulemaking for a CMMI drug pricing model<\/td>\n		April 15, 2026<\/td>\nDecember 19, 2025<\/td>\n\n
On December 19, 2025, CMS released the Global Benchmark for Efficient Drug Pricing (GLOBE) Model (CMS-5545-P)<\/a> and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model (CMS-5546-P)<\/a> Proposed Rules. Both proposed models would operate similarly to the current Medicare inflation rebates program, where manufacturers of eligible drugs pay rebates directly to CMS when they raise their prices above a benchmark.<\/div>\n
For these models, the benchmark used to calculate the rebate would be based on international pricing information, rather than domestic pricing information. Comments were due on February 23, 2026.<\/div>\n
Sec. 3. Improving upon the Inflation Reduction Act<\/strong>
\nAddressing \u201cpill penalty\u201d<\/td>\n		\u2014<\/td>\n\u2014<\/td>\nAddressing the Inflation Reduction Act\u2019s \u201cpill penalty,\u201d in which small molecule drugs are eligible for negotiation earlier than biologics, requires Congressional action.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

A year after President Trump issued Executive Order (EO) 14273, Lowering Drug Prices by Once Again Putting Americans First, federal agencies continue to take steps to advance its objectives. Although the EO\u2019s deadlines and goals are not immediately enforceable, they provide insight into the Trump Administration\u2019s drug pricing priorities and the timing of implementation. The […]<\/p>\n","protected":false},"author":24,"featured_media":7318,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","ap4_related_services":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-10778","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\nPresident Trump's EO on Lowering Drug Prices by Putting Americans First at One Year - Applied Policy<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.appliedpolicy.com\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"President Trump's EO on Lowering Drug Prices by Putting Americans First at One Year - Applied Policy\" \/>\n<meta property=\"og:description\" content=\"A year after President Trump issued Executive Order (EO) 14273, Lowering Drug Prices by Once Again Putting Americans First, federal agencies continue to take steps to advance its objectives. Although the EO\u2019s deadlines and goals are not immediately enforceable, they provide insight into the Trump Administration\u2019s drug pricing priorities and the timing of implementation. The […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.appliedpolicy.com\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\/\" \/>\n<meta property=\"og:site_name\" content=\"Applied Policy\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-06T16:02:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-06T16:09:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.appliedpolicy.com\/wp-content\/uploads\/iStock-508121363.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1254\" \/>\n\t<meta property=\"og:image:height\" content=\"836\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Emma Hammer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Emma Hammer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.appliedpolicy.com\\\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.appliedpolicy.com\\\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\\\/\"},\"author\":{\"name\":\"Emma Hammer\",\"@id\":\"https:\\\/\\\/appliedpolicy.com\\\/#\\\/schema\\\/person\\\/f9e43b9a9a0a0c3ef7ac9ba014dcba1c\"},\"headline\":\"President Trump’s EO on Lowering Drug Prices by Putting Americans First at One Year\",\"datePublished\":\"2026-04-06T16:02:44+00:00\",\"dateModified\":\"2026-04-06T16:09:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.appliedpolicy.com\\\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\\\/\"},\"wordCount\":1377,\"image\":{\"@id\":\"https:\\\/\\\/www.appliedpolicy.com\\\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.appliedpolicy.com\\\/staging\\\/7403\\\/wp-content\\\/uploads\\\/iStock-508121363.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.appliedpolicy.com\\\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\\\/\",\"url\":\"https:\\\/\\\/www.appliedpolicy.com\\\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\\\/\",\"name\":\"President Trump's EO on Lowering Drug Prices by Putting Americans First at One Year - Applied Policy\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/appliedpolicy.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.appliedpolicy.com\\\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.appliedpolicy.com\\\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.appliedpolicy.com\\\/staging\\\/7403\\\/wp-content\\\/uploads\\\/iStock-508121363.jpg\",\"datePublished\":\"2026-04-06T16:02:44+00:00\",\"dateModified\":\"2026-04-06T16:09:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/appliedpolicy.com\\\/#\\\/schema\\\/person\\\/f9e43b9a9a0a0c3ef7ac9ba014dcba1c\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.appliedpolicy.com\\\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.appliedpolicy.com\\\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.appliedpolicy.com\\\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.appliedpolicy.com\\\/staging\\\/7403\\\/wp-content\\\/uploads\\\/iStock-508121363.jpg\",\"contentUrl\":\"https:\\\/\\\/www.appliedpolicy.com\\\/staging\\\/7403\\\/wp-content\\\/uploads\\\/iStock-508121363.jpg\",\"width\":1254,\"height\":836},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.appliedpolicy.com\\\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/appliedpolicy.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"President Trump’s EO on Lowering Drug Prices by Putting Americans First at One Year\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/appliedpolicy.com\\\/#website\",\"url\":\"https:\\\/\\\/appliedpolicy.com\\\/\",\"name\":\"Applied Policy\",\"description\":\"Health policy and reimbursement consulting\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/appliedpolicy.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/appliedpolicy.com\\\/#\\\/schema\\\/person\\\/f9e43b9a9a0a0c3ef7ac9ba014dcba1c\",\"name\":\"Emma Hammer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.appliedpolicy.com\\\/staging\\\/7403\\\/wp-content\\\/uploads\\\/Emma_Hammer_3-300x300.jpg\",\"url\":\"https:\\\/\\\/www.appliedpolicy.com\\\/staging\\\/7403\\\/wp-content\\\/uploads\\\/Emma_Hammer_3-300x300.jpg\",\"contentUrl\":\"https:\\\/\\\/www.appliedpolicy.com\\\/staging\\\/7403\\\/wp-content\\\/uploads\\\/Emma_Hammer_3-300x300.jpg\",\"caption\":\"Emma Hammer\"},\"description\":\"Health Policy Manager\",\"url\":\"https:\\\/\\\/www.appliedpolicy.com\\\/staging\\\/7403\\\/author\\\/emma-hammer\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"President Trump's EO on Lowering Drug Prices by Putting Americans First at One Year - Applied Policy","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.appliedpolicy.com\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\/","og_locale":"en_US","og_type":"article","og_title":"President Trump's EO on Lowering Drug Prices by Putting Americans First at One Year - Applied Policy","og_description":"A year after President Trump issued Executive Order (EO) 14273, Lowering Drug Prices by Once Again Putting Americans First, federal agencies continue to take steps to advance its objectives. Although the EO\u2019s deadlines and goals are not immediately enforceable, they provide insight into the Trump Administration\u2019s drug pricing priorities and the timing of implementation. The […]","og_url":"https:\/\/www.appliedpolicy.com\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\/","og_site_name":"Applied Policy","article_published_time":"2026-04-06T16:02:44+00:00","article_modified_time":"2026-04-06T16:09:34+00:00","og_image":[{"width":1254,"height":836,"url":"https:\/\/www.appliedpolicy.com\/wp-content\/uploads\/iStock-508121363.jpg","type":"image\/jpeg"}],"author":"Emma Hammer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Emma Hammer","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.appliedpolicy.com\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\/#article","isPartOf":{"@id":"https:\/\/www.appliedpolicy.com\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\/"},"author":{"name":"Emma Hammer","@id":"https:\/\/appliedpolicy.com\/#\/schema\/person\/f9e43b9a9a0a0c3ef7ac9ba014dcba1c"},"headline":"President Trump’s EO on Lowering Drug Prices by Putting Americans First at One Year","datePublished":"2026-04-06T16:02:44+00:00","dateModified":"2026-04-06T16:09:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.appliedpolicy.com\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\/"},"wordCount":1377,"image":{"@id":"https:\/\/www.appliedpolicy.com\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\/#primaryimage"},"thumbnailUrl":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-content\/uploads\/iStock-508121363.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.appliedpolicy.com\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\/","url":"https:\/\/www.appliedpolicy.com\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\/","name":"President Trump's EO on Lowering Drug Prices by Putting Americans First at One Year - Applied Policy","isPartOf":{"@id":"https:\/\/appliedpolicy.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.appliedpolicy.com\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\/#primaryimage"},"image":{"@id":"https:\/\/www.appliedpolicy.com\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\/#primaryimage"},"thumbnailUrl":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-content\/uploads\/iStock-508121363.jpg","datePublished":"2026-04-06T16:02:44+00:00","dateModified":"2026-04-06T16:09:34+00:00","author":{"@id":"https:\/\/appliedpolicy.com\/#\/schema\/person\/f9e43b9a9a0a0c3ef7ac9ba014dcba1c"},"breadcrumb":{"@id":"https:\/\/www.appliedpolicy.com\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.appliedpolicy.com\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.appliedpolicy.com\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\/#primaryimage","url":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-content\/uploads\/iStock-508121363.jpg","contentUrl":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-content\/uploads\/iStock-508121363.jpg","width":1254,"height":836},{"@type":"BreadcrumbList","@id":"https:\/\/www.appliedpolicy.com\/president-trumps-eo-on-lowering-drug-prices-by-putting-americans-first-at-one-year\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/appliedpolicy.com\/"},{"@type":"ListItem","position":2,"name":"President Trump’s EO on Lowering Drug Prices by Putting Americans First at One Year"}]},{"@type":"WebSite","@id":"https:\/\/appliedpolicy.com\/#website","url":"https:\/\/appliedpolicy.com\/","name":"Applied Policy","description":"Health policy and reimbursement consulting","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/appliedpolicy.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/appliedpolicy.com\/#\/schema\/person\/f9e43b9a9a0a0c3ef7ac9ba014dcba1c","name":"Emma Hammer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-content\/uploads\/Emma_Hammer_3-300x300.jpg","url":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-content\/uploads\/Emma_Hammer_3-300x300.jpg","contentUrl":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-content\/uploads\/Emma_Hammer_3-300x300.jpg","caption":"Emma Hammer"},"description":"Health Policy Manager","url":"https:\/\/www.appliedpolicy.com\/staging\/7403\/author\/emma-hammer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/posts\/10778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/comments?post=10778"}],"version-history":[{"count":6,"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/posts\/10778\/revisions"}],"predecessor-version":[{"id":10788,"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/posts\/10778\/revisions\/10788"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/media\/7318"}],"wp:attachment":[{"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/media?parent=10778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/categories?post=10778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/tags?post=10778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}